bioMérieux Statistics
Total Valuation
bioMérieux has a market cap or net worth of 13.02 billion. The enterprise value is 13.18 billion.
| Market Cap | 13.02B |
| Enterprise Value | 13.18B |
Important Dates
The next estimated earnings date is Friday, February 27, 2026.
| Earnings Date | Feb 27, 2026 |
| Ex-Dividend Date | Jun 9, 2025 |
Share Statistics
| Current Share Class | 118.07M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.08% |
| Shares Change (QoQ) | +0.02% |
| Owned by Insiders (%) | 0.05% |
| Owned by Institutions (%) | 18.08% |
| Float | 44.73M |
Valuation Ratios
The trailing PE ratio is 29.34 and the forward PE ratio is 19.25.
| PE Ratio | 29.34 |
| Forward PE | 19.25 |
| PS Ratio | 2.69 |
| PB Ratio | 2.82 |
| P/TBV Ratio | 3.97 |
| P/FCF Ratio | 25.23 |
| P/OCF Ratio | 14.08 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.75, with an EV/FCF ratio of 25.53.
| EV / Earnings | 29.69 |
| EV / Sales | 2.69 |
| EV / EBITDA | 10.75 |
| EV / EBIT | 15.78 |
| EV / FCF | 25.53 |
Financial Position
The company has a current ratio of 2.27, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.27 |
| Quick Ratio | 1.30 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.49 |
| Debt / FCF | 1.15 |
| Interest Coverage | 45.70 |
Financial Efficiency
Return on equity (ROE) is 9.49% and return on invested capital (ROIC) is 12.61%.
| Return on Equity (ROE) | 9.49% |
| Return on Assets (ROA) | 8.23% |
| Return on Invested Capital (ROIC) | 12.61% |
| Return on Capital Employed (ROCE) | 16.14% |
| Weighted Average Cost of Capital (WACC) | 7.65% |
| Revenue Per Employee | 334,969 |
| Profits Per Employee | 30,711 |
| Employee Count | 14,754 |
| Asset Turnover | 0.77 |
| Inventory Turnover | 1.81 |
Taxes
In the past 12 months, bioMérieux has paid 162.54 million in taxes.
| Income Tax | 162.54M |
| Effective Tax Rate | 27.18% |
Stock Price Statistics
The stock price has decreased by -6.54% in the last 52 weeks. The beta is 0.66, so bioMérieux's price volatility has been lower than the market average.
| Beta (5Y) | 0.66 |
| 52-Week Price Change | -6.54% |
| 50-Day Moving Average | 132.44 |
| 200-Day Moving Average | 116.22 |
| Relative Strength Index (RSI) | 34.56 |
| Average Volume (20 Days) | 92 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, bioMérieux had revenue of 4.84 billion and earned 443.81 million in profits. Earnings per share was 3.72.
| Revenue | 4.84B |
| Gross Profit | 2.72B |
| Operating Income | 826.54M |
| Pretax Income | 598.00M |
| Net Income | 443.81M |
| EBITDA | 1.17B |
| EBIT | 826.54M |
| Earnings Per Share (EPS) | 3.72 |
Balance Sheet
The company has 446.86 million in cash and 594.72 million in debt, with a net cash position of -147.86 million.
| Cash & Cash Equivalents | 446.86M |
| Total Debt | 594.72M |
| Net Cash | -147.86M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 4.62B |
| Book Value Per Share | 39.13 |
| Working Capital | 1.49B |
Cash Flow
In the last 12 months, operating cash flow was 925.07 million and capital expenditures -409.04 million, giving a free cash flow of 516.03 million.
| Operating Cash Flow | 925.07M |
| Capital Expenditures | -409.04M |
| Free Cash Flow | 516.03M |
| FCF Per Share | n/a |
Margins
Gross margin is 56.27%, with operating and profit margins of 17.08% and 9.17%.
| Gross Margin | 56.27% |
| Operating Margin | 17.08% |
| Pretax Margin | 12.35% |
| Profit Margin | 9.17% |
| EBITDA Margin | 24.25% |
| EBIT Margin | 17.08% |
| FCF Margin | 10.66% |
Dividends & Yields
This stock pays an annual dividend of 1.02, which amounts to a dividend yield of 0.91%.
| Dividend Per Share | 1.02 |
| Dividend Yield | 0.91% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | -0.08% |
| Shareholder Yield | 0.83% |
| Earnings Yield | 3.41% |
| FCF Yield | 3.96% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
bioMérieux has an Altman Z-Score of 6.89 and a Piotroski F-Score of 7.
| Altman Z-Score | 6.89 |
| Piotroski F-Score | 7 |